KR20180112561A - Composition for preventing, improving or treating fatty liver diseases, hyperlipidemia and constipation comprising Phragmitis Rhizoma and Humulus japonicus extract - Google Patents

Abstract

The present invention relates to a composition having Phragmites rhizome and Humulus japonicus extracts as active ingredients for preventing, improving, or treating fatty liver, hyperlipidemia, and constipation and, more specifically, to a food composition including having Phragmites rhizome and Humulus japonicus extracts as active ingredients for preventing or improving one or more diseases selected from a group consisting of fatty liver, hyperlipidemia, and constipation or a pharmaceutical composition for preventing or treating one or more diseases selected from a group consisting of fatty liver, hyperlipidemia, and constipation. A method of the present invention can be useful for preventing or treating fatty liver and hyperlipidemia or preventing or treating constipation using a composition including Phragmites rhizome and Humulus japonicus extracts or including mixture of Phragmites rhizome, Humulus japonicus, and Chinese quince.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention, improvement or treatment of fatty liver, hyperlipidemia and constipation, which comprises an extract of Aspergillus oryzae as an active ingredient,

The present invention relates to a composition for prevention, improvement or treatment of fatty liver hyperlipidemia and constipation, comprising as an active ingredient a caspase and a chrysanthemum extract. More particularly, the present invention relates to a composition for preventing, ameliorating or treating constipation, , Or a pharmaceutical composition for the prevention or treatment of one or more diseases selected from the group consisting of fatty liver, hyperlipidemia and constipation.

Fatty liver means fat accumulation in liver cells and medically refers to a disease state in which fat exceeds 5% or more of total liver weight. Liver disease including liver disease is the cause of death in 40-50 adult population in developed countries Is regarded as a serious disease next to cancer. About 30% of the population of major countries, including the developed countries, have fatty liver disease, 20% of them progress to liver cirrhosis, and about half of liver cirrhosis patients die of liver disease within 10 years of diagnosis.

Fatty liver can be divided into alcoholic fatty liver disease and nonalcoholic fatty liver disease (NAFLD) due to obesity, diabetes, hyperlipidemia, and drug.

Non-alcoholic fatty liver disease refers to a wide range of diseases, including simple inflammatory reactions in patients without excessive alcohol consumption, and which develops thereby, including inflammation of hepatocytes, liver fibrosis and cirrhosis. Non-alcoholic fatty liver disease is divided into primary and secondary by cause. Primary is caused by hypercholesterolemia, diabetes, or obesity, which is characteristic of metabolic syndrome. Secondary cause is nutritional cause (rapid weight loss, starvation, It is known to be caused by toxic substances (poisonous bacteria, bacterial toxins), metabolic causes and other factors. The incidence of nonalcoholic fatty liver disease associated with diabetes and obesity, an important feature of the primary metabolic syndrome, is known to occur in approximately 50% of diabetic patients, approximately 76% of obese patients, and almost all obese diabetic patients (Gupte P et al., 2004). The incidence of hepatitis was 18-36% in patients with increased levels of alanine aminotransferase (ALT) and diabetic patients (Braillon A et al., 1985).

Until now, there has been no established treatment for nonalcoholic fatty liver disease because nonalcoholic fatty liver disease is associated with diverse factors such as diabetes, obesity, coronary artery disease, and lifestyle habits. The effects of diabetes or obesity therapy on fatty liver disease have been reported. Orlistat, which is used as a treatment for oral obesity, has been shown to induce liver histologic improvement in patients with hepatitis (Hussein et al. 2007), and metformin has been shown to reduce serum liver enzyme levels, necrotic inflammation and fibrosis in nonalcoholic fatty liver patients without diabetes (Bugianesi et al., 2005). In addition, thiazolidinedione (TZD) -based drugs, agonists of PPAR (peroxisome proliferatoractivated receptor), inhibit fat accumulation in liver and muscle, and direct anti-fibrosis in the animal model of nonalcoholic fatty liver disease (Galli A et al., 2002). However, there are few medicines currently available for the pharmacological treatment of fatty liver, and only exercise and diet are recommended.

On the other hand, constipation is stiff and dry compared to when it is healthy, and the number of stools and the amount of stool is significantly reduced, and there are symptoms with discomfort or physiological disorder at the time of bowel movement. In order to improve and cure these constipation symptoms, it is recommended that foods containing a lot of fiber such as sweet potatoes, green vegetables, konjacs, fruits and meats are consumed. However, It is a very difficult reality for young women with a small number of times to consume these foods. Accordingly, the use of herbal medicine and herbal medicine excellent in the therapeutic effect of constipation has increased the demand for tea and beverage which can be easily consumed without side effects.

Accordingly, the present inventors have conducted studies using various natural materials in order to develop a novel substance having a high effect of preventing or treating fatty liver, hyperlipidemia and constipation and having few side effects. As a result, Hyperlipidemia and constipation, and thus completed the present invention.

Accordingly, an object of the present invention is to provide a food composition for preventing or ameliorating at least one disease selected from the group consisting of fatty liver, hyperlipemia, and constipation, which comprises Angelica keiskei koidz.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating one or more diseases selected from the group consisting of fatty liver, hyperlipemia, and constipation, which comprises as an effective ingredient, camel root extract and chrysanthemum extract.

In order to achieve the above object, the present invention provides a food composition for preventing or ameliorating at least one disease selected from the group consisting of fatty liver, hyperlipidemia, and constipation, which comprises an extract of Angelica keiskei and a chrysanthemum extract as an active ingredient.

In order to accomplish still another object of the present invention, the present invention provides a pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of fatty liver, hyperlipemia and constipation, which comprises Angelica keiskei koidz.

Hereinafter, the present invention will be described in detail.

The present invention provides a food composition for preventing or ameliorating at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation, which comprises Angelica keiskei koidz. And Chrysanthemum extract as an active ingredient.

The 'nongge' of the present invention is a reed at a time when the ears are not yet eaten, and the nature is cold and the taste is sweet. It has the effect of stopping the nausea, nausea and vomiting by lowering the fever, treating the symptoms of thirst and dryness of the mouth, , Pulmonary tuberculosis, lung abscess, and has the effect of detoxifying fish poison. In addition, pharmacological actions such as diuretic, antipyretic, liver protection, and hematopoietic function have been reported.

The present invention is based on the ground of Humulus japonicus Siebold et Zuccarini (Mulberry and Moraceae), which is mainly composed of foliage-bearing vine stalks, and has fruit. Uchucho grows in the streams, on the sides of the roads, at the foot of mountains, and when the leaves are thick in summer, the outposts are cut and dried in the shade. The taste is sweet and spicy and has a cold temperament. It has been proved that Yuko has antihypertensive action against blood pressure lowering effect, diuretic effect and Gram positive bacteria. Since then, fever, chest tightness and thirst have been developed, and the fever and heat of pulmonary tuberculosis, digestive disorders, acute gastroenteritis, It is used for edema, diarrhea, dysentery, cystitis, urethritis, 淋 证, urinary stone, hypertension, swelling and boils.

The 'fatty liver disease' of the present invention means a state in which more fat is accumulated compared to normal liver. Fatty liver can be divided into alcoholic fatty liver due to excessive drinking, non-alcoholic fatty liver due to obesity, diabetes, hyperlipidemia, drug and the like. Alcoholic fatty liver is caused by a high intake of alcohol, which promotes fat synthesis in the liver and does not allow normal energy metabolism. Non-alcoholic fatty liver is associated with metabolic syndrome such as obesity, adult type diabetes, and hyperlipidemia. Continuous ingestion of excessive calories leads to accumulation of fat cells in the body and liver, and secretion of various substances (cytokines) And includes various diseases ranging from mild fatty liver to chronic hepatitis and cirrhosis. Preferably a non-alcoholic fatty liver disease or a simple fatty liver.

The hyperlipidemia of the present invention increases the amount of cholesterol and triglyceride-bearing lipoproteins in the blood serum due to an abnormality of lipid metabolism, and thus the content of major lipids (cholesterol, triglyceride, phospholipid, free fatty acid) Hyperlipidemia is diagnosed when the total cholesterol level is more than 240 mg / dl and the triglyceride level is more than 200 mg / dl. As a cause of hyperlipemia, hyperlipidemia often occurs due to an increase in specific lipid in the blood due to genetic factors, but it can also be caused by environmental factors such as obesity, diabetes, alcohol, stress, smoking.

The "constipation" of the present invention means that when an excessive force is required at the bowel movement, when the bowel movement is excessively hardened, when the bowel movement is incomplete or when there is a sense of closing the anus rectum, . The causes of constipation are secondary focal locality diseases, systemic diseases, drug use and primary cause of movement disorders of the colon, and anorectal dysfunctions. More than 90% of constipation is a constipation caused by a primary cause of secondary cause is unknown, it is called functional or idiopathic constipation.

The present invention provides a food composition for prevention or amelioration of at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation, wherein the weight ratio of the lambs and the juice of the composition is 1: 0.5 to 5. More preferably, the ratio of the weight of the camber and the camber may be 1: 1 to 3, and most preferably the weight ratio of camber and camber may be 1: 1.

In the examples of the present invention, camel and chrysanthemum extract were mixed in a weight ratio of 1: 1-3, and the total amount was prepared to be 500 mg / kg.

The present invention provides a food composition for preventing or ameliorating at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation, further comprising a neck and an extract in the composition. More preferably, the ratio of the weight to the nose, throat, and neck may be 1: 1: 1.

The "throat" of the present invention is a medicinal product made of ripe fruit of Chaenomeles sinensis (Thouin) Koehne of Rosaceae, which is warm in nature and slightly tasteless. When the muscles are not bending, the lower paralytic spasm, when the muscles are not turning back to the throat, it is used for angina pectoris, dirt burning, and indigestion. In addition, pharmacological actions have been reported to have the effects of inhibiting arthritis edema, inhibiting multiple cancers, and alleviating herniated disc herniation.

Examples of the extraction solvent of the extract of the present invention include alcohols having 1 to 6 carbon atoms such as water, ethanol, methanol, propanol, isopropanol and butanol, acetone, ether, chloroform, ethyl acetate , And organic solvents such as methylene chloride, hexane, cyclohexane, petroleum ether, diethyl ether, benzene, and the like. The roots and rhizome extracts of the present invention can be extracted preferably using at least one solvent selected from the group consisting of water, ethanol, chloroform, ethyl acetate and 1-butanol, and most preferably, extracted with water as a solvent .

The composition for food using the ragweed and chrysanthemum extract or the mixture of ragweed, rhododendron and chrysanthemum according to the present invention may be used for functional food, nutritional supplement, health food and food additives Includes all forms. The types can be prepared in various forms according to conventional methods known in the art. They can be manufactured in the form of links and drunk, granulated, encapsulated and powdered. The food composition of the present invention may be prepared in the form of a composition by mixing with known substances or active ingredients known to be effective for preventing, improving or treating fatty liver disease.

For example, as a health food, the food composition itself of the present invention may be prepared in the form of tea, juice, and drink and then consumed, granulated, encapsulated, and powdered. In addition, the food composition of the present invention may be prepared in the form of a composition by mixing with known substances or active ingredients known to have effects of reducing body fat, improving cholesterol, and lowering blood pressure.

Functional foods also include beverages (including alcoholic beverages), fruits and their processed foods (such as canned fruits, bottled, jam, maalmalade, etc.), fish, meats and processed foods such as ham, Etc.), breads and noodles (for example, udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, Vegetable protein, retort food, frozen food, various seasonings (for example, soybean paste, soy sauce, sauce, etc.) by adding the composition for food of the present invention.

The preferred content of the food composition according to the present invention is not particularly limited, but is preferably 0.01 to 50% by weight based on the total weight of the final food product. In order to use the food composition of the present invention in the form of a food additive, it may be used in the form of powder or concentrate.

The present invention provides a pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of fatty liver, hyperlipemia, and constipation, which comprises Angelica keiskei koidz. And Chrysanthemum extract as an active ingredient.

The present invention provides a pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation, which further comprises a neck and an extract in the composition.

The pharmaceutical composition according to the present invention may be formulated into a suitable form together with a lavender and a chrysanthemum extract or a lavender, a chrysanthemum and a mixture with a neck or pharmacologically acceptable carrier, and may further contain excipients or diluents have. &Quot; Pharmaceutically acceptable " as used herein refers to a nontoxic composition that is physiologically acceptable and does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, or the like when administered to humans.

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, it may contain various drug delivery materials used for oral administration to peptide preparations. In addition, the carrier for parenteral administration may contain water, a suitable oil, a saline solution, an aqueous glucose and a glycol, and may further contain a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, etc. in addition to the above components. Other pharmaceutically acceptable carriers and preparations can be found in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).

The composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration Lt; / RTI >

The pharmaceutical composition of the present invention can be formulated into oral preparations or parenteral administration preparations according to the administration route as described above.

In the case of a preparation for oral administration, the composition of the present invention may be formulated into a powder, a granule, a tablet, a pill, a sugar, a tablet, a liquid, a gel, a syrup, a slurry, . For example, an oral preparation can be obtained by combining the active ingredient with a solid excipient, then milling it, adding suitable auxiliaries, and then processing the mixture into a granular mixture. Examples of suitable excipients include, but are not limited to, sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose and the like, fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant. Further, the pharmaceutical composition of the present invention may further comprise an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In the case of a preparation for parenteral administration, it can be formulated by a method known in the art in the form of injection, cream, lotion, external ointment, oil, moisturizer, gel, aerosol and nasal aspirate. These formulations are described in Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, Pa., 1995, which is a commonly known formulary for all pharmaceutical chemistries.

 The total effective amount of the composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol administered over a prolonged period of time in multiple doses. In the pharmaceutical composition of the present invention, the content of the active ingredient may be varied depending on the degree of the disease. Preferably, the total preferred dose of the pharmaceutical composition of the present invention may be from about 0.01 μg to 10,000 mg, preferably from 0.1 μg to 500 mg, and most preferably from 100 mg to 500 mg per kg body weight of the patient per day. However, the dosage of the pharmaceutical composition may be determined depending on various factors such as the formulation method, administration route and frequency of treatment, as well as the patient's age, body weight, health condition, sex, severity of disease, diet and excretion rate, It will be possible to determine the appropriate effective dose of the composition of the present invention by those of ordinary skill in the art in view of this point. The pharmaceutical composition according to the present invention is not particularly limited to its formulation, administration route and administration method as long as the effect of the present invention is exhibited.

In the examples of the present invention, a high fat diet was administered to mice to induce fatty liver disease. Oral administration was carried out using a combination of mugwort, chrysanthemum extract, neck and extract, mugwort extract + mulberry extract, mugwort extract + The extracts were prepared at the weight ratio of 3: 1, 2: 1, 1: 1, 1: 2, 1: 3 and administered orally. The liver tissue was extracted from the mouse. After the liver cells were cultured and the oil red o staining was performed, the amount of fat was increased when the high fat diet (HFD) was performed than when the normal diet (ND) When the extract was treated, the amount of fat decreased. In addition, it was confirmed that when each mixture was treated, the fat amount was reduced as compared with the group treated with nonggeuna, rhizoma, or neck and extract alone (see Fig. 1).

In another embodiment of the present invention, as described above, the mouse induced by fatty liver is administered orally, alone or in combination, with lice, thymus, or throat and extract. After extracting and pulverizing the liver tissues from the mice, the neutral lipids were quantified using the kit. As a result, it was confirmed that the neutral lipids decreased when each extract was treated. It was confirmed that the neutral lipid was further reduced when the cholesterol + cholesterol was mixed, and it was confirmed that the amount of neutral cholesterol was lowest when the cholestyramine and cholesterol were mixed at a weight ratio of 1: 1 (see FIG. 2).

In another embodiment of the present invention, as described above, the mouse induced by fatty liver is administered orally, alone or in combination, with lice, thymus, or throat and extract. The expression levels of FAS (fatty acid synthase) and SCD1 (Stearoy-CoA desaturase-1) were measured by RT-PCR after extracting liver tissues from mice. FAS and SCD1 The expression level of FAS and SCD1 was decreased in the case of the combination of the canine + neck, the canine + oocyte, and the oocyte + neck. 1, the expression amount of FAS and SCD1 was the smallest (see Figs. 3 and 4).

In another embodiment of the present invention, blood was extracted from orally administered to the mice induced by fatty liver, as described above, either alone or in combination, and the blood was extracted. Using an ELISA kit, TNF-α and adiponectin ), The concentration of TNF-α was decreased and adiponectin was increased when each extract was treated. It was confirmed that the combination of canine + neck, canine + ulcer, ulcer + In one case, it was confirmed that the concentration of TNF-α was further decreased and adiponectin was further increased. In addition, it was confirmed that the concentration of TNF-α was the lowest when the mixture of Angelica keiskei kerosene and Rhizoma tendon was mixed at a weight ratio of 2: 1, and it was confirmed that the concentration of adiponectin was the highest when the mixture was mixed at a weight ratio of 1: 1 5 and Fig. 6).

Accordingly, the present invention provides a composition for preventing, ameliorating or treating fatty liver, hyperlipidemia and constipation, which comprises an extract of Angelica keiskei and Rhizoma extract as an active ingredient. The method of the present invention can be usefully used to prevent or treat fatty liver, hyperlipemia, or prevent or ameliorate constipation by using a composition comprising candy and chrysanthemum extract or a mixture comprising candy, chopsticks and neck.

FIG. 1 shows the result of culturing cells extracted from liver and staining with Oil red o solution (ND: normal diet, HFD: high fat diet, high fat diet, low fat diet, 3.
FIG. 2A is a graph showing the determination of neutral lipids in the liver of mice administered with the extracts of roots, necks, and yuchos and the mixture (HFD: high fat diet, 1: roots, 2: 3.
FIG. 2B is a graph showing the determination of neutral lipids in the liver of a mouse to which a mixture of squamous and juvenile extracts was administered in a weight ratio different from that of the extract (HFD: high fat diet, 1: In addition,
FIG. 3A is a graph showing the expression of FAS (fatty acid synthase) expressed by RT-PCR using mRNA extracted from liver of mice, mice, and rats administered with the mixture (HFD: High fat diet, high fat diet, low fat diet, low fat diet, high fat diet, high fat diet.
FIG. 3B is a graph showing the expression level of FAS (fatty acid synthase) by RT-PCR after extracting mRNA from the liver of a mouse to which a mixture of squamous cell carcinoma and goat juice having different weight ratio was administered (HFD : High fat diet (high fat diet), 1: follicle, 3: follicle.
FIG. 4A is a graph showing the expression level of SCD1 (Stearoyl-CoA desaturase-1) by RT-PCR after extracting mRNA from the liver of mice administered with the extracts of squamous cell carcinoma, HFD: High fat diet, 1: noodles, 2: neck and 3: cholesterol.
FIG. 4B is a graph showing the expression levels of SCD1 (Stearoyl-CoA desaturase-1) by RT-PCR using mRNA extracted from the liver of a mouse to which a mixture of squamous and juvenile extracts was administered in different weight ratios (HFD: High fat diet, 1: noodles, 3: chow).
FIG. 5A is a graph showing the concentration of TNF-α in the blood by ELISA in the blood of a mouse administered with a combination of soleus, throat, and yucho extracts and a mixture (HFD: high fat diet, 1: nogeun, 2: neck, and 3: chorus).
FIG. 5B is a graph showing the concentration of TNF-α in the blood by ELISA in the blood of a mouse to which a mixture having a weight ratio different from that of a single extract of Angelica keiskei koidz. ), 1: noose, 3:
FIG. 6A is a graph showing the concentration of adiponectin in the blood by ELISA in the blood of a mouse administered with a single extract and a mixture of rabbit, throat, and uricosum (HFD: high fat diet) , 1: follicle, 2: neck, and 3: follicle).
FIG. 6B is a graph showing the concentration of adiponectin in the blood by ELISA in the blood of a mouse to which a mixture of squamous and perennial extracts was administered at a different weight ratio (HFD: high fat diet 1), 1: inferior, 3: inferior).

Hereinafter, the present invention will be described in detail.

However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

<Experimental Method>

Manufacture of carrageenan, rhinorrhea, and throat and extracts.

Phragmitis Rhizoma, Chrysanthemum morifolium and Chrysanthemum were crushed and 10 times as much water as each weight was added and extracted by heating at 90 to 100 ° C for 5 to 15 hours. The extract was filtered using a 25 micron filter, and the filtered extract was concentrated to 26 bx at a concentration of 70-75 ° C. The concentrated material was dried using a spray dryer. Then, the mixture was prepared by mixing the mixture at a ratio by weight of 1: 1 to 3: 1: 1 to 3, and the mixture was prepared by mixing the mixture of weevil, liquorice and sorghum in a weight ratio of 1: 1: 1.

Animal experiment

6-week-old C57BL / 6 mice were purchased and used. After a sufficient feed of normal diet and water was set at room temperature of 22 ± 2 ° C, humidity of 50 ~ 70%, illumination time of 12 hours (08:00 ~ 20:00) and illumination of 150 ~ 300 Lux, Was used for the experiment.

High Fat Diet (HFD) feeds were fed from a central laboratory animal for 8 weeks to induce nonalcoholic fatty liver disease. At this time, factors that might affect the experimental results in feed composition were excluded. Then, oral administration was carried out so that the total amount was 500 mg / kg in combination with egg root extract, chrysanthemum extract, neck and extract, egg root extract + chrysanthemum extract, egg root extract + neck and extract, neck and extract +

&Lt; Example 1 >

Influence of Angelica keiskei and Chrysanthemum mixture on liver

In order to investigate the effect of ginseng extract and ginseng extract on the liver, the following experiment was conducted.

According to the above experimental method, a mouse with high-fat diet (HFD) was administered with the extract of Angelica japonica (1), the extract of the neck and the extract of Chrysanthemum japonica (3) 1 + 3), extracts from the neck and extracts (2 + 3). After the frozen section was prepared from the liver tissue obtained from the mouse, 0.5% oil red o reagent (Sigma) was added and allowed to stand at room temperature for staining. The cells were then washed five times with PBS and then observed using a microscope (Axiostarplus; Carl Zeiss, Germany).

As a result, as shown in FIG. 1, when the high fat diet (HFD) was performed, the fat amount was increased and the fat amount was decreased when each extract was treated. In addition, the amount of fat was lower when each mixture was treated, compared to the group treated with soleus, ochoko, or neck and extract alone. In addition, it was found that the amount of fat was lower when the mixture (1 + 2, 1 + 3, 2 + 3) was treated than when each extract was treated alone.

&Lt; Example 2 >

Effect of Mixture of Rhizome and Rhizoma on the Amount of Triglyceride

In order to investigate the effects of nonggue and rhizome extract on the amount of triglyceride in the liver, the following experiment was conducted.

According to the above experimental method, a mouse with high-fat diet (HFD) was administered with the extract of Angelica japonica (1), the extract of the neck and the extract of Chrysanthemum japonica (3) 1 + 3), extracts from the neck and extracts (2 + 3). Then, 0.5 g of liver tissue was placed in PBS, followed by pulverization, followed by centrifugation to obtain a supernatant to prepare a sample. Triglyceride assay kit (Abcam) was used to quantify the amount of neutral lipids incorporated in the sample according to the manufacturer's instructions.

The results are shown in Fig.

The neutral lipid was increased in the high fat diet compared with the control diet, and the neutral lipid decreased in each of the treatments. In addition, the neutral lipids were further decreased in the case of mixing the canine + the neck, the canine + the ulcer, the ulcer + the neck (Fig. 2A) than the case of each extract alone.

In addition, when the root and root extracts were mixed and treated in different ratios (weight ratio: 3: 1, 2: 1, 1: 1, 1: 2, 1: 3 weight ratio) 1, the amount of neutral grains was the lowest.

It was confirmed that the effect of the treatment of the mixture on the neutral fat deposition was better than that of the case of the treatment of the hair follicle, the hair follicle, the hair follicle, and the extract of the hair follicle. The effect of suppressing triglyceride deposition was the best.

&Lt; Example 3 >

Effects of Mixture of Rhizobium and Rhizobium on the Production of Triglyceride

In order to investigate the effect of the mulberry and perilla extracts on the production of neutrophil in the liver, the following experiment was conducted.

According to the above experimental method, a mouse with high-fat diet (HFD) was administered with the extract of Angelica japonica (1), the extract of the neck and the extract of Chrysanthemum japonica (3) 1 + 3), extracts from the neck and extracts (2 + 3), and some of the extracts were used. Liver tissues were treated with TRIaol (Invitrogen) and homogenized. RNA was then extracted and cDNA synthesized according to methods known in the art. Then, the amount of expression of FAS (fatty acid synthase) and SCD1 (Stearoy-CoA desaturase-1) was measured using a real-time RT-PCR method. The primers used in the real-time RT-PCR are shown in Table 1 below.

Primer Information designation order SEQ ID NO: FAS forward tgatagccgg tatgtcgggg One FAS reverse agaccgcttg ggtaatccat 2 SCD1 forward gcacctccct ccggaaatga 3 SCD1 reverse tactccagct tgggcggggg 4 β-actin forwrad tatcgctgcg ctggtcgtcg 5 β-actin reverse ccttctgacc cattcccacc 6

The results are shown in Fig. 3 and Fig.

The expression levels of FAS and SCD1 were higher in the high fat diet compared to the control group. When FAS and SCD1 were mixed, (Fig. 3A, Fig. 4A).

When the mixture was treated with different amounts of canine and chrysanthemum extracts in different ratios (weight ratio: 3: 1, 2: 1, 1: 1, 1: 2, 1: 3 weight ratio) : 1, the expression level of FAS and SCD1 was the lowest (FIG. 3B, FIG. 4B).

These results indicate that the expression of FAS and SCD1, which are involved in lipidogenesis synthesis, is decreased in the case of treatment of the mixture than in the case of the treatment of the hair follicle, It was confirmed that the expression level of FAS and SCD1 significantly decreased.

<Example 4>

Effects of Mixture of Rhizobium and Rhizobium on the Production of Triglyceride

In order to investigate the effects of nonggue and rhizome extracts on the antiinflammatory activity in the body, the following experiment was conducted.

According to the above experimental method, a mouse with high-fat diet (HFD) was administered with the extract of Angelica japonica (1), the extract of the neck and the extract of Chrysanthemum japonica (3) 1 + 3), and extracts from the neck and the extract + 2/3. The amount of TNF-alpha, an inflammatory cytokine, and adiponectin, an anti-inflammatory adipokine, was measured using an ELISA kit (R & D systems) according to the manufacturer's instructions.

As a result, as shown in FIG. 5, the concentration of TNF-α was higher in the case of high-fat diet than in the control, and the amount of TNF-α was higher than that of the control alone The concentration of TNF-a decreased (FIG. 5A). In addition, when lambskin and chrysanthemum extract were mixed and treated in different ratios (weight ratio of lambskin: rhizome = 3: 1, 2: 1, 1: 1, 1: 2, 1: 3) Was mixed at a weight ratio of 2: 1, the concentration of TNF-? Was the lowest (FIG. 5B).

As shown in FIG. 6, adiponectin was decreased in the high-fat diet compared to the control group, and the amount of adiponectin was decreased by the addition of the canine + neck, the canine + ulcer, In one case, adiponectin was found to increase. When the mixture of double sheath and ursuos was mixed and treated in different ratios (weevil: sheep: 3: 1, 2: 1, 1: 1, 1: 2, 1: 3 weight ratio) , The concentration of adiponectin was the highest.

It was confirmed that TNF-α was decreased and adiponectin was increased by high fat diet in the case of treatment of the mixture, compared with the case of treating alone, with or without herring root, It was confirmed that a remarkable effect was obtained.

As described above, the method of the present invention can be usefully used for preventing or treating fatty liver, hyperlipemia, or preventing or treating constipation by using a composition comprising calendula and chrysanthemum extract or a composition comprising calendula, .

<110> SUN, YUAN LU          JEONG, JI HOON <120> Composition for prevention, improving or treating fatty liver          diseases, hyperlipidemia and constipation comprising Phragmites          Rhizoma and Humulus japonicus extract <130> NP17-0015 <160> 6 <170> Kopatentin 2.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> FAS forward <400> 1 tgatagccgg tatgtcgggg 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> FAS reverse <400> 2 agaccgcttg ggtaatccat 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> SCD1 forward <400> 3 gcacctccct ccggaaatga 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> SCD1 reverse <400> 4 tactccagct tgggcggggg 20 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> beta-actin forwrad <400> 5 tatcgctgcg ctggtcgtcg 20 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> beta-actin reverse <400> 6 ccttctgacc cattcccacc 20

Claims (7)

And at least one disease selected from the group consisting of fatty liver, hyperlipidemia, and constipation, wherein the composition comprises atorvastatin and chrysanthemum extract as an active ingredient.
2. The food composition according to claim 1, wherein the composition has a weight ratio of lambskin and yellowness ratio of 1: 0.5 to 5. 5. A food composition for preventing or improving at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation.
The food composition according to claim 1, wherein the composition further comprises a nourishment and an extract. The composition for preventing or improving at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation.
The food composition according to claim 1, wherein the fatty liver disease is a non-alcoholic fatty liver disease or a simple fatty liver, wherein the composition is for prevention or improvement of at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation.
A herbal extract, a herbal extract and a chrysanthemum extract as an active ingredient, a hyperlipemia and a constipation.
[Claim 7] The pharmaceutical composition according to claim 5, wherein the composition further comprises a neck and an extract. The pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation.
The pharmaceutical composition according to claim 5, wherein the fatty liver disease is a non-alcoholic fatty liver disease or a simple fatty liver. The pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of fatty liver, hyperlipidemia and constipation.

Images